147252-84-4Relevant articles and documents
Fluorinated Olefinic Lactams: The Case of Amino Acids - Preparation and Mechanistic Studies
Bartoszak-Adamska, El?bieta,Go?dyn, Mateusz,Koroniak, Henryk,Koroniak-Szejn, Katarzyna,Salamon-Krokosz, Katarzyna,Siod?a, Tomasz
, (2022/03/17)
Herein, we report the synthesis of analogues of amino acids with a monofluorovinyl moiety. Interestingly, we have found that cyclization of the obtained products proceeds easily in all cases. The cyclization process has not previously been observed at this reaction stage, and such fluorinated lactams derived from phenylalanine, valine, alanine have not been described before.
Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design
Das, Kalyan,De Jonghe, Steven,Gu, Weijie,Herdewijn, Piet,Martinez, Sergio,Nguyen, Hoai,Rozenski, Jef,Schols, Dominique,Singh, Abhimanyu K.
, (2021/08/24)
HIV-1 reverse transcriptase (RT) plays a central role in the viral life cycle, and roughly half of the FDA-approved anti-HIV drugs are targeting RT. Nucleoside analogs (NRTIs) require cellular phosphorylation for binding to RT, and to bypass this rate-limiting path, we designed a new series of acyclic nucleoside phosphonate analogs as nucleoside triphosphate mimics, aiming at the chelation of the catalytic Mg2+ ions via a phosphonate and/or a carboxylic acid group. Novel synthetic procedures were developed to access these nucleoside phosphonate analogs. X-ray structures in complex with HIV-1 RT/dsDNA demonstrated that their binding modes are distinct from that of our previously reported compound series. The impact of chain length, chirality and linker atom have been discussed. The detailed structural understanding of these new compounds provides opportunities for designing new class of HIV-1 RT inhibitors.
HETEROCYCLIC COMPOUNDS
-
Paragraph 0224; 0281, (2020/12/29)
Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including salts of the compound) and methods of synthesizing the same. Also provided are methods of treating Hepatitis B viral (HBV) infections using a compound of formula (I), or pharmaceutically acceptable salts thereof.
